Table 1. Patient, disease and treatment characteristics of the patients enrolled in nimotuzumab expanded access program.
| Pt Id | Age | Sex | Diagnose | Tumor location | Previous therapy | Nimotuzumab administration (Combination) | Number of doses | Best response | Survival time (months) |
|---|---|---|---|---|---|---|---|---|---|
| DVM-01 | 14 | F | AA | Temporal | Surgery/RT | CTP | 106 | CR | 63.87 |
| JLGP-02 | 11 | M | AA | Occipital | Surgery/RT | CTP | 18 | CR | 43.77 |
| ARU-03 | 13 | M | AA | Fronto-temporal | Surgery/RT | CTP | 10 | SD | 64.07 |
| AAF-04 | 14 | M | AA | Intraventricular | Surgery/RT | CTP | 87 | CR | 49.57 |
| VRG-05 | 18 | F | AA | Temporo-occipital | Surgery/RT | CTP | 82 | CR | 57.73 |
| AFR-06 | 16 | F | AA | Frontal | Surgery/RT | CTP | 100 | PR | 59.53 |
| LARI-07 | 18 | M | AA | Occipital | Surgery/RT | CTP | 104 | CR | 61.60 |
| YGH-08 | 13 | F | GBM | Parietal | Surgery/RT | CTP | 67 | CR | 32.67 |
| GLM-09 | 17 | F | AA | Occipital | Surgery/RT | CTP | 8 | PR | 46.20 |
| LPS-10 | 16 | F | AA | Thalamus | Surgery/RT | CTP | 10 | PD | 6.50 |
| MRQ-11 | 4 | F | AA | Fourth ventricle | Surgery/RT | CTP | 20 | PD | 9.17 |
| ACR-12 | 8 | F | GBM | Parieto-occipital | Surgery | RT/CTP | 14 | CR | 5.27 |
| MTR-13 | 2 | F | GBM | Intraventricular | Surgery | CTP | 12 | PD | 9.37 |
| RSP-14 | 16 | F | AA | Parietal | Surgery/RT/CTP | monotherapy | 16 | PD | 6.0 |
| OPI-15 | 15 | F | GBM | Frontal | Surgery | RT/CTP | 20 | PD | 19.93 |
| RHE-16 | 8 | F | AA | Thalamus | Surgery/RT/CTP | monotherapy | 8 | PD | 2.07 |
| AAF-17 | 4 | F | AA | Thalamus | Surgery/RT/CTP | monotherapy | 10 | PD | 3.07 |
| SSP-18 | 14 | F | AA | Frontal | Surgery/RT | CTP | 26 | PR | 27.70 |
| RAJD-19 | 13 | F | AA | Temporal | Surgery/RT | CTP | 106 | CR | 56.50 |
| AIT-20 | 11 | F | AA | Spinal cord Level C3-C6 | Surgery | RT/CTP | 30 | SD | 15.20 |
| CJBO-21 | 15 | M | AA | Fronto-parietal | Surgery | RT/CTP | 19 | CR | 7.33 |
| EVL-22 | 10 | M | AA | Temporo-occipital | Surgery | RT/CTP | 19 | PR | 7.33 |
| KYSB-23 | 7 | M | AA | Parietal | Surgery/RT | CTP | 9 | SD | 1.00 |
GBM, glioblastoma multiforme; AA, anaplastic astrocytoma; RT, radiotherapy; CTP, chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.